We have read with interest the article by Pauly et al.[1], describing the use of
methylphenidate and coprescribed psychotropic medications in children and adults in a four …

Correspondence Vanessa Pauly, Laboratoire de santé publique EA 3279, CEReSS—
Centre d'Etudes et de Recherche sur les services de santé et la qualité de vie, Centre …

Purpose To identify overuse of methylphenidate and to investigate patterns of overuse in
relation to sociodemographic and clinical characteristics. Patients and methods Swedish …

Aim The aim of the present study was to characterize patterns of use of methylphenidate
(MPH), a prescription stimulant medication recommended in the treatment of attention deficit …

Context ADHD is the most common mental disorder in school-aged children. In France,
methylphenidate is the only drug authorized for ADHD. Here, we describe the pattern of …

Introduction Prevalence estimates for ADHD have therefore been at the core of an
international debate in the last two decades. In France, the only available study carried out …

Background Despite a decreasing population of children and adolescents, the cumulative
total amount of dispensed methylphenidate (MPH), the first-choice treatment of attention …

Methylphenidate (MPH) is the most common first-line therapy for ADHD in Europe 1.
Many studies have examined its effectiveness and have shown a response rate of around …

Attention deficit hyperactivity disorder (ADHD) is one of the most common
neurodevelopmental disorders. It was once thought to be a disorder affecting only children …

Background Methylphenidate (MPH) is the most common drug treatment of attention
deficit/hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in …